IL29125A - Preparations for the treatment of hyperacidity in the stomach containing a history of 2, 3, - Dichloro-6 - Sulfamoil Quinoxaline - Google Patents

Preparations for the treatment of hyperacidity in the stomach containing a history of 2, 3, - Dichloro-6 - Sulfamoil Quinoxaline

Info

Publication number: IL29125A
Authority: IL; Israel
Prior art keywords: active ingredient; sulfamoyl; composition according; compositions; dichloro
Prior art date: 1966-12-28

Application number

IL29125A

Other languages

English (en)

Hebrew (he)

Original Assignee

Merck & Co Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1966-12-28

Filing date

1967-12-13

Publication date

1971-07-28

1967-12-13 Application filed by Merck & Co Inc filed Critical Merck & Co Inc

1971-07-28 Publication of IL29125A publication Critical patent/IL29125A/en

Links

239000000203 mixture Substances 0.000 title claims description 19
230000002496 gastric effect Effects 0.000 title description 9
206010020601 Hyperchlorhydria Diseases 0.000 title description 3
REZAAULTHORKFB-UHFFFAOYSA-N 2,3-dichloroquinoxaline-6-sulfonamide Chemical class N1=C(Cl)C(Cl)=NC2=CC(S(=O)(=O)N)=CC=C21 REZAAULTHORKFB-UHFFFAOYSA-N 0.000 title 1
239000004480 active ingredient Substances 0.000 claims description 12
239000002253 acid Substances 0.000 claims description 9
229910052757 nitrogen Inorganic materials 0.000 claims description 7
SPSSDDOTEZKOOV-UHFFFAOYSA-N 2,3-dichloroquinoxaline Chemical group C1=CC=C2N=C(Cl)C(Cl)=NC2=C1 SPSSDDOTEZKOOV-UHFFFAOYSA-N 0.000 claims description 6
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 5
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
150000003839 salts Chemical class 0.000 claims description 4
150000001875 compounds Chemical class 0.000 claims description 3
125000000623 heterocyclic group Chemical group 0.000 claims description 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
125000005842 heteroatom Chemical group 0.000 claims description 2
229910052739 hydrogen Inorganic materials 0.000 claims description 2
239000001257 hydrogen Substances 0.000 claims description 2
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 2
125000001424 substituent group Chemical group 0.000 claims description 2
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 2
229910052717 sulfur Inorganic materials 0.000 claims description 2
239000011593 sulfur Substances 0.000 claims description 2
230000000767 anti-ulcer Effects 0.000 claims 2
125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 1
150000001412 amines Chemical class 0.000 description 4
238000000034 method Methods 0.000 description 4
239000000243 solution Substances 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
208000008469 Peptic Ulcer Diseases 0.000 description 3
230000009858 acid secretion Effects 0.000 description 3
239000002775 capsule Substances 0.000 description 3
210000004211 gastric acid Anatomy 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
239000008101 lactose Substances 0.000 description 3
239000007788 liquid Substances 0.000 description 3
230000001175 peptic effect Effects 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
235000009328 Amaranthus caudatus Nutrition 0.000 description 2
240000001592 Amaranthus caudatus Species 0.000 description 2
241000416162 Astragalus gummifer Species 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
229940121948 Muscarinic receptor antagonist Drugs 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
229920001615 Tragacanth Polymers 0.000 description 2
235000012735 amaranth Nutrition 0.000 description 2
239000004178 amaranth Substances 0.000 description 2
229940069428 antacid Drugs 0.000 description 2
239000003159 antacid agent Substances 0.000 description 2
230000001458 anti-acid effect Effects 0.000 description 2
239000002585 base Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
239000000812 cholinergic antagonist Substances 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
238000009472 formulation Methods 0.000 description 2
239000008187 granular material Substances 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
210000000653 nervous system Anatomy 0.000 description 2
XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 2
230000003248 secreting effect Effects 0.000 description 2
230000028327 secretion Effects 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
238000003756 stirring Methods 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
235000010487 tragacanth Nutrition 0.000 description 2
239000000196 tragacanth Substances 0.000 description 2
229940116362 tragacanth Drugs 0.000 description 2
ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
241000237858 Gastropoda Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
OXBOABAOQWBSIV-UHFFFAOYSA-N [N]S(N)(=O)=O Chemical group [N]S(N)(=O)=O OXBOABAOQWBSIV-UHFFFAOYSA-N 0.000 description 1
125000003545 alkoxy group Chemical group 0.000 description 1
230000001078 anti-cholinergic effect Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
229940125717 barbiturate Drugs 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
125000003963 dichloro group Chemical group Cl* 0.000 description 1
125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
238000007907 direct compression Methods 0.000 description 1
208000000718 duodenal ulcer Diseases 0.000 description 1
230000000694 effects Effects 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000012458 free base Substances 0.000 description 1
210000004051 gastric juice Anatomy 0.000 description 1
210000001156 gastric mucosa Anatomy 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
230000035876 healing Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
DILRJUIACXKSQE-UHFFFAOYSA-N n',n'-dimethylethane-1,2-diamine Chemical compound CN(C)CCN DILRJUIACXKSQE-UHFFFAOYSA-N 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
239000000047 product Substances 0.000 description 1
125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000000376 reactant Substances 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
230000001629 suppression Effects 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
239000003204 tranquilizing agent Substances 0.000 description 1
230000002936 tranquilizing effect Effects 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

IL29125A 1966-12-28 1967-12-13 Preparations for the treatment of hyperacidity in the stomach containing a history of 2, 3, - Dichloro-6 - Sulfamoil Quinoxaline IL29125A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US60520766A	1966-12-28	1966-12-28

Publications (1)

Publication Number	Publication Date
IL29125A true IL29125A (en)	1971-07-28

Family

ID=24422677

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL29125A IL29125A (en)	1966-12-28	1967-12-13	Preparations for the treatment of hyperacidity in the stomach containing a history of 2, 3, - Dichloro-6 - Sulfamoil Quinoxaline

Country Status (6)

Country	Link
US (1)	US3574838A (de)
AT (1)	AT278811B (de)
DE (1)	DE1617658A1 (de)
FR (1)	FR7106M (de)
GB (1)	GB1178930A (de)
IL (1)	IL29125A (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3985669A (en) *	1974-06-17	1976-10-12	The Procter & Gamble Company	Detergent compositions
DE4014937A1 (de) *	1990-05-10	1991-11-14	Bayer Ag	2,3-disubstituierte chinoxaline als leistungsfoerderer fuer tiere

1966
- 1966-12-28 US US605207A patent/US3574838A/en not_active Expired - Lifetime
1967
- 1967-12-13 IL IL29125A patent/IL29125A/en unknown
- 1967-12-21 DE DE19671617658 patent/DE1617658A1/de active Pending
- 1967-12-21 AT AT1160467A patent/AT278811B/de not_active IP Right Cessation
- 1967-12-22 GB GB58307/67A patent/GB1178930A/en not_active Expired
- 1967-12-27 FR FR133844A patent/FR7106M/fr not_active Expired

Also Published As

Publication number	Publication date
GB1178930A (en)	1970-01-21
FR7106M (de)	1969-07-15
AT278811B (de)	1970-02-10
DE1617658A1 (de)	1971-03-25
US3574838A (en)	1971-04-13

Publication	Publication Date	Title
US4929632A (en)	1990-05-29	Medicaments
US4558063A (en)	1985-12-10	Treatment of diarrhoea with 2-aminoimidazoline derivatives
IE51342B1 (en)	1986-12-10	Substituted pyrazinyl-1,2,4-oxadiazol-5-ones,a process for preparing same and a pharmaceutical composition containing same
US4226861A (en)	1980-10-07	N-Lower-alkyl 3-phenoxy-1-azetidinecarboxamides
US5922749A (en)	1999-07-13	Medicaments for treating nausea and vomiting
AU602899B2 (en)	1990-11-01	Treatment of hypertension, compounds and compositions for antihypertension and diuresis
US3885035A (en)	1975-05-20	Method for treating arrhythmia by using 1,4-bis(4 quinazolinyl) piperazines
US2753288A (en)	1956-07-03	Scopolamine lower-alkyl halide therapeutic composition
SU927111A3 (ru)	1982-05-07	Способ получени оксимэфиров или их солей
US2918406A (en)	1959-12-22	Anti-spasmodics specific for peptic ulcer
IL29125A (en)	1971-07-28	Preparations for the treatment of hyperacidity in the stomach containing a history of 2, 3, - Dichloro-6 - Sulfamoil Quinoxaline
US3086910A (en)	1963-04-23	Central nervous system depressants 3-(2'-pyridyl)-4-quinazolones
US3903159A (en)	1975-09-02	Methanesulfonamidophenyl guanidine compounds
US4576955A (en)	1986-03-18	Pyridylalkylenethiopyridyls
DE2236876C3 (de)	1981-02-12	N-Substituierte Aminocarbonsäuren und diese Verbindungen enthaltende Arzneimittel
US3993778A (en)	1976-11-23	Anti-ulcerogenic pharmaceutical compositions containing a 2-amino-3,5-dibromo-benzylamine and method of use
IE53331B1 (en)	1988-10-26	Amidinourea compositions for use in a method for relieving the discomfort of a human female attendant to menstruation
US3088869A (en)	1963-05-07	Antiemetic compositions and methods of treating nausea and vomiting
US3714363A (en)	1973-01-30	Substituted amino guanidine as anti-diabetic agents
US3266988A (en)	1966-08-16	Method of producing anti-adrenal activity
US4215130A (en)	1980-07-29	Antihypertensive compositions of N-(2,6-dichlorophenyl)-4,5-dihydro-1H-imidazol-2-amine and N-(2-chloroethyl)-N-(1-methyl-2-phenoxyethyl)-benzenemethanamine
US4098887A (en)	1978-07-04	Pharmaceutical compositions and methods of producing antiarthritic activity with bis(pyridine)gold(1+) salts
US4203984A (en)	1980-05-20	Antisecretory triazinones
US3760082A (en)	1973-09-18	Compositions containing 5-amino-3-ethyl-1-phenyl-4-pyrazolecarboxamides and methods of using the same
US3821406A (en)	1974-06-28	Therapeutic compositions containing 1-substituted biguanides and method of treating gastrointestinal disorders therewith